Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ExchangeParis (Euro)
Price€16.00
Change (%)0.00 (0.00%)
Volume25,879
Data as of 12/15/17 2:31 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
11-Dec-2017Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Dec. 11, 2017-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com ... 
 Printer Friendly Version
08-Dec-2017ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France - December 8, 2017 - ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced topline results from its Phase 2b clinical study evaluating... 
 Printer Friendly Version
16-Nov-2017Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – November 16, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Nov. 16, 2017-- Regulatory News: Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.co... 
 Printer Friendly Version
15-Nov-2017ERYTECH Announces Commencement of Trading of ADSs on Nasdaq and Full Exercise of Underwriters’ Option, Bringing Gross Proceeds of Global Offering to $144 Million
Base deal of $125 million in gross proceeds from specified categories of specialized investors closed on November 14, 2017. Announced full exercise of underwriters’ option to purchase additional American Depositary Shares (ADSs) and Ordinary Shares, with closing expected to take place on or about November 16, 2017. Will add approximately $19 million in additional gross proceeds for total of $144 million in gross proceeds. ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources